1) Halperin EC, Bentel G, Heinz ER, et al. Radiation therapy treatment planning in supratentorial glioblastoma multiforme : an analysis based on post mortem topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys 1989 ; 17 (6) : 1347-50.
2) 永根基雄. 悪性脳腫瘍の治療効果判定の画像診断. CI研究 2015 ; 36 : 103-112.
3) Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 ; 92 (3) : 205-16.
4) Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours : revised RECIST guideline (version 1.1). Eur J Cancer 2009 ; 45 (2) : 228-47.
5) Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990 ; 8 (7) : 1277-80.
6) Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for neurooncology working group. J Clin Oncol 2010 ; 28 (11) : 1963-72.
7) Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008 ; 9 (5) : 453-61.
8) van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group) : assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011 ; 12 (6) : 583-93.
9) Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered therapies for gliomas : Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012 ; 70 (1) : 234-43 ; discussion 43-4.
10) Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neurooncology : a report of the RANO working group. Lancet Oncol 2015 ; 16 (15) : e534-42.
11) Alexander BM, Brown PD, Ahluwalia MS, et al. Clinical trial design for local therapies for brain metastases : a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol 2018 ; 19 (1) : e33-42.
12) Camidge DR, Lee EQ, Lin NU, et al. Clinical trial design for systemic agents in patients with brain metastases from solid tumours : a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol 2018 ; 19 (1) : e20-32.
13) Chamberlain M, Junck L, Brandsma D, et al. Leptomeningeal metastases : a RANO proposal for response criteria. Neuro Oncol 2017 ; 19 (4) : 484-92.
14) Huang RY, Bi WL, Weller M, et al. Proposed Response Assessment and Endpoints for Meningioma Clinical Trials : Report from the Response Assessment in Neuro-Oncology (RANO) Working Group. Neuro Oncol 2018.
15) Lin NU, Lee EQ, Aoyama H, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1 : patient population, response, and progression. A report from the RANO group. Lancet Oncol 2013 ; 14 (10) : e396-406. Epub 2013/09/03.
16) Lin NU, Wefel JS, Lee EQ, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2 : neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol 2013 ; 14 (10) : e407-16. Epub 2013/09/03.
17) Nayak L, DeAngelis LM, Brandes AA, et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale : a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol 2017 ; 19 (5) : 625-35.
18) Warren KE, Vezina G, Poussaint TY, et al. Response assessment in medulloblastoma and leptomeningeal seeding tumors : recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro Oncol 2018 ; 20 (1) : 13-23.
19) de Wit MC, de Bruin HG, Eijkenboom W, et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004 ; 63 (3) : 535-7.
20) Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008 ; 26 (13) : 2192-7.
21) Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008 ; 113 (2) : 405-10.
22) Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist 2003 ; 9 (4) : 180-8.
23) Kreisl TN, Lassman AB, Mischel PS, et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 2009 ; 92 (1) : 99-105.
24) Clarke JL, Chang S. Pseudoprogression and pseudoresponse : challenges in brain tumor imaging. Curr Neurol Neurosci Rep 2009 ; 9 (3) : 241-6.
25) Nagane M NR, Narita Y, Kobayashi H, et al. Phase II study of single-agent bevacizumab in Japanese patients with reccurent malignant glioma. Jpn Clin Oncol 2012 ; 42 (10) : 887-95.
26) Brastianos PK, Batchelor TT. Vascular endothelial growth factor inhibitors in malignant gliomas. Target Oncol 2010 ; 5 (3) : 167-74.
27) Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009 ; 27 (28) : 4733-40.
28) Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly : the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012 ; 13 (7) : 707-15.
29) Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma : the Nordic randomised, phase 3 trial. Lancet Oncol 2012 ; 13 (9) : 916-26.
30) Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Bio Phys 2005 ; 63 (1) : 47-55.
31) Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Bio Phys 1991 ; 21 (1) : 109-22.
32) Back M, Gzell CE, Kastelan M, et al. Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma. Neurooncol Pract 2015 ; 2 (1) : 48-53.
33) 浅井昭, 松谷雅生, 松田忠義. 脳腫瘍放射線治療後の亜急性障害としての脳萎縮と痴呆. 癌の臨床 1987 ; 35 : 753-61.
34) 兼平千裕. 放射線脊髄症の分析-脊髄耐容線量の時間-線量関係-. 日本医放会誌 1987 ; 47 : 606-20.
35) Munk J, Peyser E, Gruszkiewicz J. Radiation induced intracranial meningiomas. Clin Radiol 1969 ; 20 (1) : 90-4.
36) Cahan WG, Woodard HQ, et al. Sarcoma arising in irradiated bone ; report of 11 cases. Cancer 1948 ; 1 (1) : 3-29.
37) Harrison MJ, Wolfe DE, Lau TS, et al. Radiationinduced meningiomas : experience at the Mount Sinai Hospital and review of the literature. J Neurosurg 1991 ; 75 (4) : 564-74.
38) Kitanaka C, Shitara N, Nakagomi T, et al. Postradiation astrocytoma. Report of two cases. J Neurosurg 1989 ; 70 (3) : 469-74.
39) Liwnicz BH, Berger TS, Liwnicz RG, et al. Radiation-associated gliomas : a report of four cases and analysis of postradiation tumors of the central nervous system. Neurosurgery 1985 ; 17 (3) : 436-45.
40) Tsang RW, Laperriere NJ, Simpson WJ, et al. Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 1993 ; 72 (7) : 2227-33.
41) Loeffler JS, Niemierko A, Chapman PH. Second tumors after radiosurgery : tip of the iceberg or a bump in the road? Neurosurgery 2003 ; 52 (6) : 1436-40 ; discussion 40-2.
42) Kestle JR, Hoffman HJ, Mock AR. Moyamoya phenomenon after radiation for optic glioma. J Neurosurg 1993 ; 79 (1) : 32-5.
43) Larson JJ, Ball WS, Bove KE, et al. Formation of intracerebral cavernous malformations after radiation treatment for central nervous system neoplasia in children. J Neurosurg 1998 ; 88 (1) : 51-6.
44) 杉山達也, 松谷雅生, 小倉弘章, 他. 小児悪性脳腫瘍放射線治療後の血管腫発生. 脳外誌 2002 ; 11 : 425-30.
45) Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas : initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996 ; 14 (2) : 556-64.
46) Ott RJ, Brada M, Flower MA, et al. Deehan BJ. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 1991 ; 27 (11) : 1356-61.
47) Chamberlain MC. Recurrent intracranial ependymoma in children : salvage therapy with oral etoposide. Pediatr Neurol 2001 ; 24 (2) : 117-21.
48) 茶山公祐, 宮村能子, 鷲尾佳奈. 小児脳腫瘍に対する経口エトポシドを使った低用量持続化学療法の安全性・有効性の検討. 日児誌 2009 ; 113 (2) : 343.
49) Newlands ES, Stevens MF, Wedge SR, et al. Temozolomide : a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997 ; 23 (1) : 35-61.
50) Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009 ; 10 (5) : 459-66.
51) Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005 ; 352 (10) : 987-96.
52) Wakabayashi T, Natsume A, Mizusawa J, et al. JCOG0911 INTEGRA study : a randomized screening phase II trial of interferonbeta plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. J Neurooncol 2018 ; 138 (3) : 627-36.
53) Gerson SL. MGMT : its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004 ; 4 (4) : 296-307.
54) 永根基雄, 口野嘉幸, 浅井昭雄. ACNU耐性とMGMTの発現. Mebio 1993 ; 10 (7) : 107-13.
55) 永根基雄. 悪性神経膠腫に対するtemozolomide化学療法における耐性機序とその克服の道筋. 専門医に求められる最新の知識. 脳外速報 2010 ; 20 : 188-97.
56) Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New Engl J Med 2000 ; 343 (19) : 1350-4.
57) Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl Journal Med 2005 ; 352 (10) : 997-1003.
58) 永根基雄. Temozolomide の有用性は確立したか? EBM癌化学療法-分子標的治療法 2011-2012 (大津敦, 古瀬純司, 中川和彦, 他), 中外医学社, 東京, 2010, p554-8.
59) van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors : a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009 ; 27 (35) : 5881-6.
60) Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009 ; 27 (35) : 5874-80.
61) Malley DS, Hamoudi RA, Kocialkowski S, et al. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 2011 ; 121 (5) : 651-61.
62) 永根基雄. ニムスチン. これだけは押さえておきたいがん化学療法の薬. 古瀬純司 (編). プロフェッショナルがんナーシング 2013 別冊 2013 : 100-1.
63) Jansen M, de Witt Hamer PC, Witmer AN, et al. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Brain res Rev 2004 ; 45 (3) : 143-63.
64) Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007 ; 25 (30) : 4722-9.
65) Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly diagnosed glioblastoma : mature progression-free results in AVAGlio. Neuro-Oncology. 2012 ; 14 (Suppl 6) : vi101-vi105.
66) Gilbert MR, Dignam J, Won M, et al. RTOG 0825 : Phase III double-blind placebo-controlled trial evaluating bevacizumab in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013 ; 31 (Suppl 18).
67) Sandmann T, Bourgon R, Garcia J, et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide : Retrospective Analysis of the AVAglio Trial. J Clin Oncol 2015 ; 33 (25) : 2735-44.
68) Wakabayashi T, Kayama T, Nishikawa R, et al. A multicentric phase I trial of interferon-beta and temozolomide combination therapy for high grade gliomas (INTEGRA Study) : the final report. J Neurooncol 2011 ; 104 : 573-577.
69) Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma : results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016 ; 3 (5) : e217-27.
70) Ferreri AJM, Ciceri F, Brandes AA, et al. MATILDE chemotherapy regimen for primary CNS lymphoma : results at a median follow-up of 12 years. Neurology 2014 ; 82 (15) : 1370-3.
71) Glass J, Won M, Schultz CJ, et al. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma : NRG Oncology RTOG 0227. J Clin Oncol 2016 ; 34 (14) : 1620-5.
72) Laack NN, O'Neill BP, Ballman KV, et al. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys 2011 ; 81 (2) : 476-82.
73) Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma : final results and long-term outcome. J Clin Oncol 2013 ; 31 (31) : 3971-9. Epub 2013/10/09.
74) Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma : CALGB 50202 (Alliance 50202). J Clin Oncol 2013 ; 31 (25) : 3061-8. Epub 2013/04/10.
75) Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma : long term outcome. J Neurosurg 1994 ; 81 (2) : 188-95.
76) Hiraga S, Arita N, Ohnishi T, et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 1999 ; 91 (2) : 221-30.
77) O'Brien PC RD, Pratt G, Liew KH, et al ; Trans-Tasman Radiation Oncology Group. Combined-modality therapy for primaly central nervous system lymphoma : long-term data from a Phase II murticenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Bio Phys 2006 ; 64 (2) : 408-13.
78) 泉本修一, 森 鑑二, 有田憲生. 中枢神経系悪性リンパ腫研究会. 悪性リンパ腫に対するHD-MTX療法の長期成績と問題点- 多施設共同臨床試験から. 第26回日本脳腫瘍学会抄録集, 愛媛, 2008, p130.
79) Gavrilovic IT, Hormigo A, Yahalom J, et al. Longterm follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006 ; 24 (28) : 4570-4.
80) Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma : the next step. J Clin Oncol 2000 ; 18 (17) : 3144-50.
81) Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007 ; 25 (30) : 4730-5.
82) Morris PG,Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma : final results and long-term outcome. J Clin Oncol 2013 ; 31 : 3971-3979.
83) Reni M, Ferreri AJ, Guha-Thakurta N, et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront highdose methotrexate. Int J Radiat Oncol Bio Phys 2001 ; 51 (2) : 419-25.
84) Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma : a randomised phase 2 trial. Lancet 2009 ; 374 (9700) : 1512-20.
85) Herrlinger U, Kuker W, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma : final report. Ann Neurol 2005 ; 57 (6) : 843-7.
86) Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy : a report of NABTT 96-07. J Clin Oncol 2003 ; 21 (6) : 1044-9.
87) Momota H, Narita Y, Miyakita Y, et al. Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. Pediatr Blood Cancer 2010 ; 55 : 577-79.
88) Momota H, Narita Y, Miyakita Y, et al. Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro Oncol 2013 ; 15 : 1445-50.
89) 松谷雅生, 藤巻高光, 柳澤隆昭. 放射線治療, 化学療法. 脳神経外科周術期管理のすべて 第4版 (松谷雅生, 他, 編), メジカルビュー社, 東京, 2014, p233-261.